Urinary Neutrophil Gelatinase Associated Lipocalin (NGAL) as an Early Marker of Acute Kidney Injury in Septic Patients

Thesis Submitted In Parital Fulfillment Of M.D Degree Of Internal Medicine

By

Dr. Ahmed Akef Fahmy

Ms sc.

Supervision By

Prof. Dr. Dawlat Mohamed Belal

Professor Of Internal Medicine
Faculty Of Medicine
Cairo University

Dr. khaled younes Mohamed

Professor Of Internal Medicine
National Research Center

Dr. Mohamed Momtaz Mohamed

Lecturer Of Internal Medicine
Faculty Of Medicine
Cairo University

Faculty Of Medicine
Cairo University
2013

Abstract

Sepsis: is a leading cause of mortality all over the world. NGAL belongs to the Lipocalin superfamily of more 20 structurally related secreted proteins that are thought to transport a variety of ligands within a barreled calyx.

The study included 30 patients with sepsis not associated with AKI and 50 septic patients with AKI for estimation of the predictive role of NGAL in AKI.

NGAL is shown to be a valid biomarker, being better positive than negative in prediction of AKI among septic group.

• Key words: NGAL – AKI - Sepsis

Contents

| Page | <u>)</u> |
|--------------------------------------|----------|
| Introduction | l |
| Review of literature : | |
| Chapter 1 : Sepsis | 1 |
| Chapter 2 : Acute Kidney Injury | 36 |
| Chapter 3: Biological Markers in AKI | 64 |
| Chapter 4: Study design and methods | 82 |
| Chapter 5: Results | 88 |
| Chapter 6: Discussion | 101 |
| Conclusion1 | 08 |
| Recommendations | 109 |
| Summary | 110 |
| References | 115 |
| Arabic summary | |

I dedicate this study to my;

Mother,

Father,

Sister,

Brothers,

and my lovely kids.

Acknowlgement

Thanks to ALLAH, the most merciful and the most gracious.

Thanks to Dr. Dawlat Belal, professor of Internal Medicine, Cairo University, I owe her a great deal of gratitude, her wide horizon of experience and kindness has helped me in this work.

I would like to thank Dr. Khaled Younes, professor of Internal Medicine, National Research Center, for his kind advices and valuable time to accomplish this study.

I am so grateful to Dr. Mohamed Momtaz, lecturer of Internal Medicine, Cairo University, who was really very helpful, careful and guided me in every step of that work to make it appear in its current image.

Thanks to Dr. Mona Anwar, assistant professor of Clinical Pathology, National Research Center, for doing laboratory work up of this study. Neither did she save her effort nor her time to accomplish this work.

I would also like to express my gratitude to everyone who has encouraged me.

List of figures

| Figure (3-1) | Iron Thievery | 75 |
|--------------|--|-----|
| Figure (4-1) | Three hypothetical receiver-operating characteristic (ROC) | 87 |
| Figure(5-1) | Comparison between the studied groups as regard serum creatinine | 93 |
| Figure(5-2) | Comparison between the studied groups as regard stages of sepsis | 94 |
| Figure(5-3) | Comparison between the studied groups as regard NGAL levels | 95 |
| Figure(5-4) | Comparison between the studied groups as regard NGAL levels | 96 |
| Figure(5-5) | Comparison between the cases and controls as regard NGAL | 97 |
| Figure(5-6) | Comparison between the NGAL levels in various AKI stages | 98 |
| Figure(5-7) | AUC of NGAL | 100 |

List of tables

| Table (3-1) | Table (3-1) Qualities and characteristics of an ideal endogenous marker of | | | | |
|---------------------|--|-----|--|--|--|
| | glomerular function | | | | |
| Table (3-2) | Factors affecting conventional markers of kidney function | | | | |
| Table (5-1) | Group I - Age and Gender | 88 | | | |
| Table (5-2) | Group I – biochemical analysis | 88 | | | |
| Table (5-3) | Group I –Sepsis stages | 89 | | | |
| Table (5-4) | Group II - Age and Gender | 89 | | | |
| Table (5-5) | Group II –biochemical analysis | 90 | | | |
| Table (5-6) | Group II –Sepsis stages | 90 | | | |
| Table (5-7) | Group II –AKI stages | 91 | | | |
| Table (5-8) | Group III – Age and Gender | 91 | | | |
| Table (5-9) | Group III – Biochemical Analysis | 92 | | | |
| Table (5-10) | Comparison between the studied groups as regard serum | 93 | | | |
| | creatinine | | | | |
| Table (5-11) | Comparison between the studied groups as regard stages of sepsis | 94 | | | |
| Table (5-12) | Comparison between the studied groups as regard uNGAL levels | 95 | | | |
| Table (5-13) | Comparison between the studied groups as regard NGAL | 96 | | | |
| | Comparison between the cases and controls as regard NGAL | 97 | | | |
| () | Comparison between the NGAL levels in various AKI stages | 98 | | | |
| Table (5-16) | Correlation between the NGAL and different data among studied groups | 99 | | | |
| Table (5-17) | Validity of NGAL in prediction of AKI among the studied | 100 | | | |
| , | groups | | | | |

List of Abbreviations

| ACCP American College of Chest Physicians ACE Angiotensin Converting Enzyme ADA American Diabetes Association ADMA Asymmetric Dimethyarginine ADQI Acute Dialysis Kidney Initiative AGE Advanced Glycemic End-products AKI Acute Kidney Injury AKIN Acute Kidney Injury Network ALI Acute Lung Injury ARBS Angiotensin Receptor Blocker ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous Cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone CRP C-Reactive Protein | | | |
|---|------|--|--|
| ADA American Diabetes Association ADMA Asymmetric Dimethyarginine ADQI Acute Dialysis Kidney Initiative AGE Advanced Glycemic End-products AKI Acute Kidney Injury AKIN Acute Kidney Injury Network ALI Acute Lung Injury ARBS Angiotensin Receptor Blocker ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous Cyclic Peritoneal Dialysis CCPD Cluster of Differentiation CGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| ADMA Asymmetric Dimethyarginine ADQI Acute Dialysis Kidney Initiative AGE Advanced Glycemic End-products AKI Acute Kidney Injury AKIN Acute Kidney Injury Network ALI Acute Lung Injury ARBS Angiotensin Receptor Blocker ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| ADQI Acute Dialysis Kidney Initiative AGE Advanced Glycemic End-products AKI Acute Kidney Injury AKIN Acute Kidney Injury Network ALI Acute Lung Injury ARBS Angiotensin Receptor Blocker ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| AGE Advanced Glycemic End-products AKI Acute Kidney Injury AKIN Acute Kidney Injury Network ALI Acute Lung Injury ARBS Angiotensin Receptor Blocker ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| AKI Acute Kidney Injury AKIN Acute Kidney Injury Network ALI Acute Lung Injury ARBS Angiotensin Receptor Blocker ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| AKIN Acute Kidney Injury Network ALI Acute Lung Injury ARBS Angiotensin Receptor Blocker ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| ALI Acute Lung Injury ARBS Angiotensin Receptor Blocker ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| ARBS Angiotensin Receptor Blocker ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| ARDS Adult Respiratory Distress Syndrome ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| ARF Acute Renal Failure ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation CGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| ATS American Thoracic Society AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation CGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| AUC Area Under Curve C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| C1 Complement Fragment 1 CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| CAPD Continuous Ambulatory Peritoneal Dialysis CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation CGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| CCPD Continuous cyclic Peritoneal Dialysis CD Cluster of Differentiation CGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| CD Cluster of Differentiation cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| cGMP Cyclic Glycosyl Monophosphate CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| CKD Chronic kidney disease CRH Corticotropin Releasing Hormone | | | |
| CRH Corticotropin Releasing Hormone | | | |
| i i | | | |
| CDD C Departing Protein | | | |
| CRP C-Reactive Protein | | | |
| CVAHD Continous VenoArterial Haemodialysis | | | |
| CVC Central Venous Catheter | | | |
| CVD Cardiovascular disease | | | |
| CVP Central Venous Pressure | | | |
| CVVHD Continous VenoVenous Haemodialysis | | | |
| DDAH Dimethylarginine Dimethylaminohydrolase | | | |
| DN Diabetic Nephropathy | | | |
| ELISA Enzyme Linked Immunosorbent Assay | | | |
| ESICM European Society of Internal Care Medicine | | | |
| ESRD End stage renal disease | | | |
| FiO2 Fraction of Inspired Oxygen | | | |
| FPG Fasting plasma glucose | 1 19 | | |
| GFR Glomerular filtration rate | | | |
| HCT Haematocrit | | | |
| ICAM IntraCellular Adhesion Molecule | | | |

| ICU | Intensive Care Unit | | |
|-----------|---|--|--|
| IHD | Intermittent Haemodialysis | | |
| IL | Interleukin | | |
| INF-alpha | Interferon-alpha | | |
| IPD | Intermittent Peritoneal Dialysis | | |
| KDIGO | Kidney Disease Improving Global Disease Outcome | | |
| MA | Microalbuminuria | | |
| MAP | Mean Arterial Pressure | | |
| MDL | Myeloid DAP12 associated Lectin | | |
| MDRD | Modification of Diet in Renal Disease | | |
| MODS | Multiple Organ Dysfunction Syndrome | | |
| NGAL | Neutrophil Gelatinase Associated Lipocalin | | |
| NKF | National kidney foundation | | |
| NO | Nitric oxide | | |
| NOD | NucleotideOligomerization Domain | | |
| PAMPs | Pathogen Associated Molecular Patterns | | |
| PCWP | Pulmonary Capillary Wedge Pressure | | |
| PMNs | Polymorphnuclear Leucocytes | | |
| pNGAL | Plasma Gelatinase Associated Lipocalin | | |
| PO2 | Oxygen saturation tension | | |
| PPR | Pattern Recognition Receptor | | |
| PRA | PreRenal Azotemia | | |
| RIFLE | Risk Injury Failure loss Endstage | | |
| RIG | Retinoic acid Inducible Gene | | |
| ROC | Reciever Operating Characteristics | | |
| RRT | Renal replacement therapy | | |
| SCCM | Society of Critical Care Medicine | | |
| Scr | Serum creatinine | | |
| ScvO2 | Central venous oxyhaemoglobin saturation | | |
| SIRS | Systemic Inflammatory Response Syndrome | | |
| SIS | Surgeal Infection Society | | |
| SLED | Sustained Low Efficiency Dialysis | | |
| SNP | Single Nucleotide Polymorphism | | |
| SPKT | Simultaneous transplantation of pancreas and kidney | | |
| TLR | Toll Like Receptor | | |
| TREM | Triggering Receptor Expressed on Myeloid cell | | |
| UAE | Urinary Albumin Excretion | | |
| UKPDS | U.K. Prospective Diabetes Study | | |
| uNGAL | Urinary Neutrophil Gelatinase Associated Lipocalin | | |
| USRDS | United States Renal Data System | | |
| VCAM | Vascular Cell Adhesion Molecule | | |

Introduction

In current clinical practice, AKI is typically diagnosed by measuring serum creatinine. Unfortunately, creatinine is an unreliable indicator of AKI (Bellomo et al., 2004). Serum creatinine varies with age, sex, muscle bulk, metabolism, drugs and hydration status. It will not change until more than 50% of kidney function has already been lost (Prasad et al., 2007). Hence identification of a novel AKI biomarker has been designated as a top priority by the American Society of Nephrology (American Society of Nephrology, 2005).

NGAL belongs to the Lipocalin superfamily of more than 20 structurally related secreted proteins that are thought to transport a variety of ligands within a barreled calyx. Human NGAL was originally identified as a 25-KD protein covalently bound to gelatinase from human neutrophil secondary granule protein (Flower et al., 2000).

Neutrophil gelatinase-associated lipocalin (NGAL) is a rapidly emerging biomarker for early detection of acute kidney injury (AKI). Seemingly NGAL levels in both plasma and urine can be used to detect AKI days before creatinine, at least when the time of insult to the kidneys is known (Bachorzewska et al., 2007).

Released by neutrophils upon activation, NGAL is also a marker of bacterial infection and systemic inflammation (Mori et al., 2005). As AKI often is associated with sepsis (Bagshaw et al., 2007) this might hamper the predictive properties of plasma NGAL as a biomarker of AKI, at least in the general intensive care unit (ICU)

setting. Whether sepsis affects the specificity of urinary NGAL as an early AKI marker is still unclear.

Few studies have investigated the predictive properties of NGAL as an AKI marker in a general ICU population. In a study by (Cruz et al., 2010) plasma NGAL was a good predictor of AKI. The Cruz study considers many factors that might confound the predictive properties of plasma NGAL. Still, sepsis incidence was almost twice as high in AKI versus non-AKI patients (Cruz et al., 2010). Similar studies on pediatric ICU patients have shown urinary NGAL to be a good predictor of AKI (Zappitelli et al., 2007). Again, in these pediatric studies AKI and sepsis coincided to a great extent.

Aim of the work

This study will be conducted to:

- Asses the effect of sepsis on urinary NGAL levels.
- Study the effect of AKI on urinary NGAL levels.
- Examine the diagnostic utility of NGAL as an early marker of AKI in patients diagnosed with sepsis. This may allow early intervention to avoid developing AKI.

Chapter 1

Sepsis

INTRODUCTION

Sepsis is a clinical syndrome that complicates severe infection. It is characterized by the cardinal signs of inflammation (vasodilation, leukocyte accumulation, increased microvascular permeability) occurring in tissues that are remote from the infection. Systemic inflammatory response syndrome (SIRS) is an identical clinical syndrome that complicates a noninfectious insult (eg: acute pancreatitis, pulmonary contusion). Current theories about the onset and progression of sepsis and SIRS focus on dysregulation of the inflammatory response, including the possibility that a massive and uncontrolled release of proinflammatory mediators initiates a chain of events that lead to widespread tissue injury. This response can lead to multiple organ dysfunction syndrome (MODS), which is the cause of the high mortality associated with these syndromes.

DEFINITIONS

Systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock were initially defined in 1991 by a consensus panel convened by the American College of Chest Physicians (ACCP) and Society of Critical Care Medicine (SCCM) (American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference, 1992) These definitions were reconsidered in 2001 during an International Sepsis Definitions Conference that included representatives from the ACCP, SCCM, American Thoracic Society (ATS), European Society of Intensive Care Medicine (ESICM), and Surgical Infection Society (SIS) (Levy et al., 2003). A practical modification of the definitions has since been published, which provides exact hemodynamic definitions for septic shock (Annane et al., 2005).